REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/07/2026
Voltar para busca
Dado oficial do USPTO
LUNAC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
06/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42
Data de depósito
27/01/2020
Data de registro
06/07/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/07/2021
Última transação
06/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
TRATOS, MARK STEVEN
Unidade examinadora
M40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Lunac Therapeutics Limited
Representantes
Matthew L. Frisbee Leason Ellis LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medical and veterinary preparationsnamely pharmaceutical preparations for the treatment of blood disordersblood clots and to prevent blood coagulation; pharmaceuticalsnamely pharmaceutical preparations for the treatment of blood disordersblood clots and to prevent blood coagulation; medicinesnamely pharmaceutical preparations for the treatment of blood disorders; therapeutic medicines and pharmaceuticalsnamely pharmaceutical preparations for the treatment of blood disorders; medical diagnostic productsnamely diagnostic preparations for medical purposes; anticoagulants; anticoagulants for the treatment of medical conditions; anticoagulants for the treatment of thrombosis and blood clots; anticoagulants for use in the discoverypreclinical and clinical development of therapeutic products and medical diagnostic products; medicines and pharmaceuticals for use in the discoverypreclinical and clinical development of therapeutic products and medical diagnostic productsnamely anticoagulants
Classe 40
custom manufacture of chemicalsmedicinespharmaceuticals and anticoagulants; custom manufacture of therapeutic products and medical diagnostic products in the nature of pharmaceuticals for the treatment of blood disordersblood clots and to prevent blood coagulation; consultancyadvisory and information in connection with all of the aforementioned servicesproviding advisory services regarding the custom manufacture of pharmaceuticals for others
Classe 42
Scientific and technological servicesproviding scientific research for medical purposes in the field of blood disordersblood clots and to prevent blood coagulation; research and design in relation to sciencetechnologypharmaceuticalsmedicinebloodthrombosis and anticoagulantsproviding scientific research for medical purposes in the field of blood disordersblood clots and to prevent blood coagulation; preparation of scientific reports on anticoagulants for medical and veterinary purposes; engineering of medicines and pharmaceuticals; bimolecular engineering of anticoagulantsthe manipulation of oral small molecules for use as anticoagulants; engineering of anticoagulants; engineering of medicines and pharmaceuticals for the treatment of thrombosis and blood clotting; scientific services relating to the discoverypreclinical and clinical development of therapeutic and medical diagnostic productsproviding scientific research for medical purposes in the field of blood disordersblood clots and to prevent blood coagulation; consultancyadvisory and information in connection with all of the aforementioned servicesadvising regarding scientific research for medical purposes in the field of blood disordersblood clots and to prevent blood coagulation
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/06/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/06/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/06/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
29/11/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/11/2021
FIMP
FINAL DISPOSITION PROCESSED
09/11/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/10/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
06/07/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/04/2021
PUBO
PUBLISHED FOR OPPOSITION
20/04/2021
GPNX
NOTIFICATION PROCESSED BY IB
18/04/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
31/03/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
31/03/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
31/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/03/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
11/03/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/03/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
11/03/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/02/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/02/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/02/2021
RFNT
REFUSAL PROCESSED BY IB
27/09/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/09/2020
RFRR
REFUSAL PROCESSED BY MPU
02/09/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/07/2020
MAFR
APPLICATION FILING RECEIPT MAILED
28/07/2020
CNRT
NON-FINAL ACTION WRITTEN
27/07/2020
DOCK
ASSIGNED TO EXAMINER
24/07/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/07/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
23/07/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LUNAC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.